Well, it seems a few people on this forum believe that 50:50 is too conservative. So, if I redo the expected value (EV) calculation based on 65:35, with a 5X uplift if successful, then OPT's expected value is $2.24, minus the discount rate of return for a wait time of 1 year and 3 months. Complications arise as Lucentis and Eylea trials are not mutually exclusive; therefore, failure in one is a strong indicator of failure in the other, and of course, success in one will foreshadow success in the other. Success in both could very well result in 8-10X valuation $6.90.
Based on the above from my perspective OPT is a strong speculative buy.
Well, it seems a few people on this forum believe that 50:50 is...
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
67.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $444.0M | |||
| Open | High | Low | Value | Volume |
| 67.0¢ | 67.0¢ | 65.5¢ | $179.9K | 271.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 66.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 67.0¢ | 56882 | 17 |
View Market Depth
| Last trade - 16.10pm 16/05/2024 (20 minute delay) ? |
|
|||||
|
Last
66.0¢ |
Change
0.000 ( 0.89 %) |
||||
| Open | High | Low | Volume | ||
| 66.5¢ | 67.0¢ | 65.8¢ | 36570 | ||
| Last updated 15.59pm 16/05/2024 ? | |||||
| OPT (ASX) Chart |